ライフサイエンスコーパス: induration

1 e countries who tested TST-positive (>/=5 mm induration).

2 lia, followed by chronic neuropathy and skin induration.

3 m away but within the area of the late-phase induration.

4 , we evaluated the distribution of skin size induration after intradermal injection of PPD among 364

5 immunity based on the extent of erythema and induration after intradermal VZV antigen injection.

6 licited dose-dependent increases in erythema/induration and cellular infiltrates.

7 d MBP1 (10 microM) each produced perceptible induration and erythema with moderate cellular infiltrat

8 t common adverse effects were injection site induration and tenderness.

9 of both a change in the size of the zone of induration and the age of the person being tested.

10 moderate injection site pain and tenderness, induration, and erythema.

11 e were more local reactions (pain, erythema, induration, and warmth) and systemic reactions (chills,

12 upplemented with BCSO, the total diameter of induration at 24 h and individual responses to tetanus t

13 t Test 2 there was a significant increase in induration at 48 h (mean, 7.8 mm; p < 0.001), no differe

14 e tuberculin skin test positive (ie, >/=5 mm induration) at enrolment received a substantial benefit

15 There were more positive results (> 15 mm induration) at Test 2 compared with Test 1 at 48 h (19 v

16 an subjects exhibited decreased erythema and induration, CD4(+) and CD8(+) T-cell infiltration, and a

17 unlikely to cause the redness, swelling, and induration characteristic of the peak (6 h) late-phase c

18 TST induration diameter and IFN-gamma responses were correla

19 hs) and clinical assessment (telangiectasia, induration, edema, and pigmentation).

20 No significant differences in PPD-induced induration, epidermal activation and thickening or numbe

21 Induration, erythema, or local pain at the injection sit

22 Adverse reactions (local redness, swelling, induration, fever>39 degrees C) were reported by 5.3% of

23 survival proportion was 84.6% for those with indurations greater than 10 mm, compared with 45.0% for

24 Two vaccinees had transient induration > 1 cm in diameter at the injection site.

25 ctively compared for 37 tuberculin-positive (induration > or = 5 mm) and 284 tuberculin-negative (ind

26 leishmanin test converted after vaccination (induration > or =5 mm) had a significantly lower frequen

27 ity (DCH) response to the third vaccination (induration >/=5 mm).

28 Positive (induration, > or =10 mm) tuberculin skin test results we

29 ubjects with positive tuberculin skin tests (induration, > or =5 mm) with purified protein derivative

30 thy, tuberculin skin test-positive (>/=15-mm induration), HIV-negative South African adults.

31 test results were recorded in millimeters of induration in 95 (25%); and 100 (27%) reported collectin

32 = .02) but slightly greater absence of skin induration in follow-up (84.5% vs 81.2%, P = .02).

33 Subjects with anergy (0 mm induration in reaction to PPD and candida antigens) were

34 ly for the marked effect of BCG-attributable induration in the very young.

35 an 10 mm, compared with 45.0% for those with indurations less than 5 mm.

36 on > or = 5 mm) and 284 tuberculin-negative (induration < or = 2 mm) persons.

37 Serial PPD induration, lymphoproliferation, and interferon-gamma re

38 ion-site erythema (n=158) and injection-site induration (n=153).

39 s 20 percent or more among most persons with induration of 10 mm or more on a tuberculin skin test an

40 ildren five years of age or younger who have induration of 10 mm or more on a tuberculin skin test.

41 ho are receiving infliximab therapy and have induration of 15 mm or more on a tuberculin skin test.

42 Leishmanin skin conversion with an induration of 5 mm or more in either group was associate

43 ercent) had a positive tuberculin skin test (induration of at least 10 mm), including 3 of the child'

44 Variant reactivity was defined as induration of less than 10 mm at 72 hours that, when rea

45 evealed an enlarged prostate with an area of induration of the left, normal rectal tone, and guaiac-n

46 Six patients displayed woody induration of the muscles of the legs, thighs, and forea

47 aracterized by an insidious onset of massive induration of the subcutaneous tissue involving the limb

48 ation take rates, lesion size, erythema, and induration or in serum neutralizing-antibody response we

49 or breast shrinkage, breast edema, tumor bed induration, or pigmentation.

50 with coincident uveitis and cutaneous tattoo induration over an 18-month period.

51 Following high-dose infection, cB6 FP induration peaked at 4 weeks and was maintained for 12 w

52 e area (r = 0.62-0.75), erythema (r = 0.39), induration (r = 0.24) and scale (r = 0.38).

53 and 11 (34%) low risk individuals developed induration resembling DTH, and the cellular infiltrates

54 ncy virus (HIV) infection is associated with induration size among tuberculin reactors, a cross-secti

55 due to cutaneous anergy, to be PPD reactors, induration size was not associated with HIV infection am

56 Median induration size was similar among HIV-seropositive (20.5

57 Smaller tuberculin test induration sizes suggest eligibility for tuberculosis ch

58 However, rates of local induration, systemic reactions, adverse events (AEs), an

59 In START-A, moderate or marked breast induration, telangiectasia, and breast oedema were signi

60 ensitivity of the TST at both 5-mm and 10-mm induration thresholds were 0.79 (5-mm: 95% CI, 0.69-0.89

61 However, lack of skin induration to intradermal injection of PPD or PPD anergy

62 Induration was not sustained in cLTalpha(-/-) FPs that c

63 Transient erythema and induration were more common after intradermal administra